TECENTRIQ + Carbo/Etop: The First FDA-Approved Treatment for 1L ES-SCLC in 20 Years 1,4

 

  • More than 40 Phase III trials evaluating other regimens have been attempted since 1970, none of which led to additional FDA approvals 5

The first FDA-approved cancer immunotherapy combination to improve overall survival in 1L ES-SCLC 1

  • Median OS was 12.3 months with TECENTRIQ + carbo/etop vs 10.3 months with placebo + carbo/etop (HR=0.70; 95% CI, 0.54, 0.91; P=0.0069) with a median follow-up of 13.9 months 1,2*
  • PD-L1 testing is not required to prescribe TECENTRIQ for ES-SCLC

*Based on OS interim analysis.

NCCN CATEGORY 1, PREFERRED: Atezolizumab (TECENTRIQ) + carbo/etop is a preferred immunotherapy/chemotherapy option (Category 1) for first-line treatment of patients with ES-SCLC in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 3†‡

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. See the NCCN Guidelines® for detailed recommendations, including other preferred options.
Category 1: based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

1L=first line; carbo/etop=carboplatin/etoposide; CI=confidence interval; ES-SCLC=extensive-stage small cell lung cancer; HR=hazard ratio; NCCN=National Comprehensive Cancer Network; OS=overall survival; PD-L1=programmed death-ligand 1; SCLC=small cell lung cancer.
 

ES-SCLC Video Series: Disease Overview

Watch a video to learn more about the prevalence, disease background, and treatment landscape of SCLC.